Core Insights - NeoGenomics, Inc. reported a full-year diluted earnings per share (EPS) of -$0.84, which missed estimates, but exceeded revenue expectations with a full-year revenue of $727 million, reflecting a 10% increase from $661 million the prior year [3][4] - In the fourth quarter, the company achieved an adjusted diluted EPS of $0.06, surpassing the Zacks Consensus Estimate of $0.04, indicating a 50% earnings surprise [3][4] - Over the past four quarters, NeoGenomics has exceeded consensus adjusted EPS estimates three times, demonstrating its ability to outperform market expectations [4][5] Financial Performance - The revenue for the quarter ending December 2025 was $190 million, exceeding the Zacks Consensus Estimate by approximately 0.9% to 1.1%, and showing a significant increase from the $172 million reported in the same period the previous year [4] - The company has surpassed consensus revenue estimates twice in the last four quarters, showcasing consistent revenue growth [5] Market Valuation and Liquidity - NeoGenomics has a negative trailing price-to-earnings (P/E) ratio of approximately -12.5 and a price-to-sales ratio of around 2.06, indicating that the market values its sales at about $2.06 for every dollar of sales [2][5] - The enterprise value to sales ratio is approximately 2.3, reflecting the company's total valuation relative to its sales [5] - With a current ratio of 4.26, NeoGenomics maintains a strong liquidity position, indicating its ability to cover current liabilities with its assets [2][5]

Financial Performance - Revenue increased by 10.1% compared to 2024[258] - Adjusted EBITDA rose by 9.5% or $3.7 million to $43.4 million compared to 2024[258] - Consolidated revenue for the year ended December 31, 2025, was $727.3 million, representing a 10.1% increase from $660.6 million in 2024, primarily driven by increased test volumes and strategic reimbursement initiatives[284] - The net loss for 2025 was $108.0 million, compared to a net loss of $78.7 million in 2024, with a basic net loss per share of $(0.84)[307] - For the year ended December 31, 2025, NeoGenomics reported a net loss of $108.0 million, compared to a net loss of $78.7 million in 2024, reflecting a year-over-year increase of 37.3% in losses[312] - Adjusted EBITDA for 2025 was $43.4 million, an increase of 9.0% from $39.6 million in 2024, indicating improved operational performance despite the net loss[312] Expenses and Costs - Cost of revenue for 2025 was $413.0 million, up 11.5% from $370.5 million in 2024, with gross profit of $314.3 million and a gross profit margin of 43.2%, down from 43.9% in 2024[286][288] - General and administrative expenses increased by $13.6 million to $273.3 million in 2025, accounting for 37.6% of revenue, compared to 39.3% in 2024[290] - Research and development expenses rose 19.0% to $37.1 million in 2025, representing 5.1% of revenue, driven by increased compensation and benefits costs[292] - Sales and marketing expenses increased by $7.4 million to $92.0 million in 2025, accounting for 12.6% of revenue, compared to 12.8% in 2024[295] - Impairment charges for 2025 were $27.8 million, including an $11.4 million impairment on InVisionFirst®-Lung intangible assets and a $15.9 million impairment on Trapelo's assets[300] Cash Flow and Liquidity - Cash provided by operating activities decreased to $5.2 million in 2025 from $7.0 million in 2024, a decline of 25.7% primarily due to higher cash used from operating results[313] - Cash used in investing activities was $12.3 million in 2025, a significant shift from cash provided of $12.9 million in 2024, driven by a $33.9 million decrease in proceeds from marketable securities[314] - Cash used in financing activities surged to $200.3 million in 2025, compared to cash provided of $4.6 million in 2024, primarily due to the repayment of the 2025 Convertible Notes[315] - As of December 31, 2025, NeoGenomics had $159.6 million in cash and cash equivalents, sufficient to support operational liquidity needs for at least the next 12 months[316] Strategic Initiatives - The acquisition of Pathline was completed in April 2025[258] - The company aims to drive targeted product launches in therapy selection and MRD through its launch excellence program[259] - Continued expansion into the community oncology market is planned, leveraging established strategic positions with community hospitals[259] - The company expects to maintain operational efficiency through automation and process improvements[259] - The company is focused on enhancing its test menu and driving down testing costs through investments in technology and automation[255] - The company anticipates an increase in research and development expenditures as it continues to invest in innovation projects and new tests[293] - The company anticipates continued growth opportunities in key markets despite an increasingly uncertain macroeconomic environment in fiscal year 2026[320] Regulatory and Market Environment - The FDA's evolving regulatory framework for Laboratory Developed Tests (LDTs) may impact compliance obligations and costs[263] - NeoGenomics is a leading provider of Heme oncology diagnostic testing and solid tumor NGS testing solutions in the U.S.[254] - The company operates under a single segment encompassing a comprehensive range of oncology diagnostic services[265] - NeoGenomics has operations in the UK, exposing it to foreign currency exchange risks, primarily in British Pounds, but currently does not hedge these risks[324] - The company issued $345.0 million in 2028 Convertible Notes with a fixed annual interest rate of 0.25%, which mitigates economic interest rate exposure[323] Interest Income and Expense - Interest income decreased by 50.8% to $9.1 million in 2025, primarily due to a reduction in the average balance of invested cash and lower interest rates[302] - Interest expense decreased by 43.3% to $3.8 million in 2025, reflecting the maturity and settlement of the Company's 2025 Convertible Notes[305]

NeoGenomics (NasdaqCM:NEO) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsAbhishek Jain - EVP of Finance and Incoming CFOJeff Sherman - CFOKendra Webster - VP of Investor RelationsTony Zook - CEOWarren Stone - Chief Commercial OfficerConference Call ParticipantsAndrew Brackman - Equity Research AnalystAndrew Cooper - Equity Research AnalystBill Bonello - Equity Research AnalystDan Brennan - Equity Research AnalystDavid Westenberg - Equity Research AnalystMark Massaro - Equity Resear ...

NeoGenomics (NasdaqCM:NEO) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Company ParticipantsAbhishek Jain - EVP of Finance and Incoming CFOJeff Sherman - CFOKendra Webster - VP of Investor RelationsTony Zook - CEOWarren Stone - Chief Commercial OfficerConference Call ParticipantsAndrew Brackman - Equity Research AnalystAndrew Cooper - Equity Research AnalystBill Bonello - Equity Research AnalystDan Brennan - Equity Research AnalystDavid Westenberg - Equity Research AnalystMark Massaro - Equity Resear ...

NeoGenomics (NasdaqCM:NEO) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Speaker11Good morning, and welcome to the NeoGenomics fourth quarter and full year 2025 financial results call. Please be advised that today's conference is being recorded. I will now turn the call over to Kendra Webster with NeoGenomics. The floor is yours.Speaker8Thank you, Kelly, and good morning, everyone. Welcome to the NeoGenomics fourth quarter and full year 2025 financial results call. With me today to discuss the results ...

NeoGenomics (NEO) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +57.90%. A quarter ago, it was expected that this operator of cancer-focused testing laboratories would post earnings of $0.02 per share when it actually produced earnings of $0.03, delivering a surprise of +50%.Over th ...

Q4 and FY 2025 Financial Results February 17, 2026 Nasdaq: NEO Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company"). Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "would," "may," "will," "believe, ...

five minutes prior to the call. The participant access code provided for this call is 825997. The live webcast may be accessed by visiting the Investor Relations section of our website at [ir.neogenomics.com]. A replay of the webcast NeoGenomics Reports Fourth Quarter and Full Year 2025 ResultsFeb 17, 2026 7:05 AM Eastern Standard Time# NeoGenomics Reports Fourth Quarter and Full Year 2025 ResultsShare---Full-year revenue increased 10% to $727 million; Full-year clinical revenue grew 15%, or 13% excluding t ...

Key Takeaways NeoGenomics launches PanTracer Pro to streamline testing for advanced solid tumors.NEO says the assay pairs DNA/RNA sequencing of 500 genes with IHC to guide therapy and trials.NeoGenomics reported Q4 sales near $190M, up 11%, and expects double-digit growth in 2026.NeoGenomics, Inc. (NEO) recently announced the availability of its new pan-solid tumor assay, PanTracer Pro, designed to help clinicians navigate increasingly complex molecular testing workflows to make informed decisions for patie ...

(unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.## ContactsInvestor Contact Kendra Webster [InvestorRelations@neogenomics.com]Media Contact Andrea Sampson [asampson@sampsonprgroup.com]Industry:- [Genetics]- [Hospitals]- [Medical Devices]- [ ...